Biointaxis is an academic spin-off focused on the development of gene therapies for neurodegenerative disorders. Biointaxis lead product is a gene therapy product for Friedreich ataxia.
| Website | http://www.biointaxis.com |
| Employees | 7 (6 on RocketReach) |
| Founded | 2018 |
| Technologies |
JavaScript
,
HTML
,
PHP
+8 more
(view full list)
|
| Industry | Biotechnology Research, Business Services General, Health Care, Business Services |
| Keywords | Gene Therapy, Genome Editing, Neurological Disorders, Novel Therapies, Genetic Diseases, Ataxia Treatment, Gene Editing, Clinical Trials, Biotechnology, Pharmaceutical Research, Drug Development, Rare Diseases, Genetic Engineering, Molecular Biology, Therapeutics, Biopharma, Precision Medicine, Cell Therapy |
| Competitors | GE HealthCare, Roche, Thermo Fisher Scientific, BD, Merck Group, Agilent Technologies, Illumina, MilliporeSigma, Bio-Rad Laboratories, QIAGEN +40 more (view full list) |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 541 Companies, NAICS Code 54 Companies |
Looking for a particular BIOINTAXIS SL employee's phone or email?
Ivelisse Sanchez is the Founder and Chief Scientific Officer (CSO)-Director Científico of BIOINTAXIS SL.
6 people are employed at BIOINTAXIS SL.
BIOINTAXIS SL is based in Badalona, Catalonia.
The NAICS codes for BIOINTAXIS SL are [541, 54].
The SIC codes for BIOINTAXIS SL are [87, 873].